Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10533730rdf:typepubmed:Citationlld:pubmed
pubmed-article:10533730lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10533730lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:10533730lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:10533730lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:10533730lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:10533730lifeskim:mentionsumls-concept:C0555278lld:lifeskim
pubmed-article:10533730lifeskim:mentionsumls-concept:C1273870lld:lifeskim
pubmed-article:10533730lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:10533730lifeskim:mentionsumls-concept:C0521115lld:lifeskim
pubmed-article:10533730lifeskim:mentionsumls-concept:C0060696lld:lifeskim
pubmed-article:10533730pubmed:issue2lld:pubmed
pubmed-article:10533730pubmed:dateCreated1999-11-23lld:pubmed
pubmed-article:10533730pubmed:abstractTextWe report results of a conservative treatment for brain metastases from malignant melanoma with a combination of irradiation and chemotherapy (fotemustine and/or DTIC). To date, 12 patients have been treated. There was a complete remission of the brain metastases in four patients. In two patients a partial remission was observed. The mean survival of the responder was 8.2 months (95% confidence interval 3.8-12.6 months). The most common side effects were thrombocytopenia, leukopenia, and alopecia. Altogether, the treatment was well tolerated. As the outcome of patients with brain metastases from malignant melanoma is generally poor, this combined chemo- and radiation therapy may provide improved care for such patients.lld:pubmed
pubmed-article:10533730pubmed:languageenglld:pubmed
pubmed-article:10533730pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10533730pubmed:citationSubsetIMlld:pubmed
pubmed-article:10533730pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10533730pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10533730pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10533730pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10533730pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10533730pubmed:statusMEDLINElld:pubmed
pubmed-article:10533730pubmed:monthJunlld:pubmed
pubmed-article:10533730pubmed:issn0167-594Xlld:pubmed
pubmed-article:10533730pubmed:authorpubmed-author:UlrichJJlld:pubmed
pubmed-article:10533730pubmed:authorpubmed-author:GollnickHHlld:pubmed
pubmed-article:10533730pubmed:authorpubmed-author:GademannGGlld:pubmed
pubmed-article:10533730pubmed:issnTypePrintlld:pubmed
pubmed-article:10533730pubmed:volume43lld:pubmed
pubmed-article:10533730pubmed:ownerNLMlld:pubmed
pubmed-article:10533730pubmed:authorsCompleteYlld:pubmed
pubmed-article:10533730pubmed:pagination173-8lld:pubmed
pubmed-article:10533730pubmed:dateRevised2006-4-24lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:meshHeadingpubmed-meshheading:10533730...lld:pubmed
pubmed-article:10533730pubmed:year1999lld:pubmed
pubmed-article:10533730pubmed:articleTitleManagement of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.lld:pubmed
pubmed-article:10533730pubmed:affiliationDepartment of Dermatology and Venereology, Otto von Guericke University Medical School, Magdeburg, Germany. Jens.Ulrich@Medizin.Uni-Magdeburg.DElld:pubmed
pubmed-article:10533730pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10533730lld:pubmed